Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8644316 | 0.85 | FFAR3 (0.40) | FFAR3 | |
| SCHEMBL16699606 | 0.79 | FFAR3 (0.43) | FFAR3 | |
| SCHEMBL14690934 | 0.79 | FFAR3 (0.30) | FFAR3 | |
| SCHEMBL8643338 | 0.79 | FFAR3 (0.36) | FFAR3 | |
| SCHEMBL28344677 | 0.77 | NSD2 (0.48) | GRM1NSD2 | |
| SCHEMBL8641820 | 0.75 | FFAR3 (0.44) | FFAR3NSD2CA1CA2CA9 | |
| SCHEMBL106415 | 0.75 | — | — | |
| SCHEMBL11636429 | 0.75 | FFAR3 (0.33) | FFAR3 | |
| SCHEMBL25590381 | 0.75 | FFAR3 (0.39) | FFAR3 | |
| SCHEMBL31369012 | 0.73 | MEN1 (0.38) | FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11357718-B2 | Polymer-based antimicrobial compositions and methods of use thereof | eXion labs Inc. (US) | 2022-06-14 | — | — | US | claimed |
| CN-112980015-A | Preparation method of antibacterial fluorine-containing film | 浙江省化工研究院有限公司 | 2021-06-18 | — | — | CN | claimed |
| US-10130655-B2 | Composition and method for pre-surgical skin disinfection | GOJO INDUSTRIES, INC. (US) | 2018-11-20 | — | — | US | claimed |
| US-20170224722-A1 | COMPOSITION AND METHOD FOR PRE-SURGICAL SKIN DISINFECTION | GOJO INDUSTRIES, INC. (US) | 2017-08-10 | — | — | US | claimed |
| US-20170064946-A1 | ANTIMICROBIAL ALCOHOL FOAM COMPOSITIONS AND METHODS OF PREPARATION | SILVER POINT FINANCE, LLC, AS COLLATERAL AGENT | 2017-03-09 | — | — | US | claimed |
| US-9516877-B2 | Antimicrobial alcohol foam compositions and methods of preparation | GOJO INDUSTRIES, INC. (US) | 2016-12-13 | — | — | US | claimed |
| US-20150080478-A1 | ANTIMICROBIAL ALCOHOL FOAM COMPOSITIONS AND METHODS OF PREPARATION | SILVER POINT FINANCE, LLC, AS COLLATERAL AGENT | 2015-03-19 | — | — | US | claimed |
| EP-2830419-A1 | ANTIMICROBIAL ALCOHOL FOAM COMPOSITIONS AND METHODS OF PREPARATION | GOJO Industries, Inc. (US) | 2015-02-04 | — | — | EP | claimed |
| CN-104202980-A | Antimicrobial alcohol foam compositions and methods of preparation | GOJO IND INC | 2014-12-10 | — | — | CN | claimed |
| EP-2471559-B1 | Antiviral method | GOJO IND INC (US) | 2014-11-26 | — | — | EP | claimed |
| US-8450378-B2 | Antiviral method | GOJO INDUSTRIES, INC. (US) | 2013-05-28 | — | — | US | claimed |
| US-20130052156-A1 | ANTIVIRAL METHOD | GOJO INDUSTRIES, INC. (US) | 2013-02-28 | — | — | US | claimed |
| EP-2471559-A2 | Antiviral method | Gojo Industries, Inc. (US) | 2012-07-04 | — | — | EP | claimed |
| US-20120134952-A1 | Antiviral Method | SILVER POINT FINANCE, LLC, AS COLLATERAL AGENT | 2012-05-31 | — | — | US | claimed |
| US-8119115-B2 | Antiviral method | GOJO INDUSTRIES, INC. (US) | 2012-02-21 | — | — | US | claimed |
| US-20090018213-A1 | ANTIVIRAL METHOD | SILVER POINT FINANCE, LLC, AS COLLATERAL AGENT | 2009-01-15 | — | — | US | claimed |
| EP-1820396-A1 | Composition and method for pre-surgical skin disinfection | Gojo Industries, Inc. (US) | 2007-08-22 | — | — | EP | claimed |
| US-20070185216-A1 | ANTIVIRAL METHOD | PNC BANK, NATIONAL ASSOCIATION, AS AGENT | 2007-08-09 | — | — | US | claimed |
| US-20070184016-A1 | Composition and method for pre-surgical skin disinfection | SILVER POINT FINANCE, LLC, AS COLLATERAL AGENT | 2007-08-09 | — | — | US | claimed |
| US-20070184013-A1 | Antiviral method | SILVER POINT FINANCE, LLC, AS COLLATERAL AGENT | 2007-08-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11357718-B2 | Polymer-based antimicrobial compositions and methods of use thereof | PARG, POLM, DNMT1 | FFAR3 4364/4885GRM1 3469/4885NSD2 2339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.